.png){kind=icon}
.png){kind=icon}
Return
Perioperative immunotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis of neoadjuvant and adjuvant strategies
.png){kind=icon}
OA
AI
C
I
P
R
A
L
B
G
P
V
J
L
W
M
W
W
L
DOI：10.1016/j.clon.2026.104281.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Perioperative immunotherapy demonstrates meaningful antitumor activity in muscle-invasive bladder cancer across neoadjuvant, adjuvant, and combined perioperative strategies. • Neoadjuvant immunotherapy-based regimens achieved a pooled pathological complete response rate of 38.92% in 42 prospective studies comprising 6,006 patients. • Neoadjuvant strategies showed encouraging pooled survival outcomes, with overall survival of 82.33% and recurrence-free survival of 77.78%. • Grade 3–4 immune-related adverse events were infrequent in the neoadjuvant setting, supporting an acceptable perioperative safety profile.
Keywords:
Bladder cancer
Neoadjuvant
Systematic Review
Immunotherapy
Meta-analysis
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3
Papers:
4.7K
Citations:
4.7K
Organization
Cited Papers